Published in Blood Weekly, January 26th, 2006
Early research has shown this anti-sickling agent to be a highly effective and relatively nontoxic treatment for sickle cell disease (SCD). The compound expands Xechem's existing products for treating SCD.
Previously, Xechem acquired the license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, for the manufacture, marketing and distribution...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.